<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12414">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00488514</url>
  </required_header>
  <id_info>
    <org_study_id>TXA107977</org_study_id>
    <nct_id>NCT00488514</nct_id>
  </id_info>
  <brief_title>Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents</brief_title>
  <official_title>Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to determine long-term safety of TREXIMET (sumatriptan/naproxen
      sodium) in adolescents for the acute treatment of migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed to determine long-term safety of TREXIMET (sumatriptan/naproxen
      sodium) in adolescents (aged 12 to 17 years) for the acute treatment of migraine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Drug-related Adverse Events</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with a drug-related adverse event (AE). Frequency threshold for reporting a drug-related AE: &gt;=2% participants recorded as having at least one occurrence of a reported drug-related AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event Categorized by Severity</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with at least one mild (an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities), moderate (an event that is sufficiently discomforting to interfere with normal everyday activities), or severe adverse event (an event that prevents normal everyday activities) was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event Categorized Over Time</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with an adverse event occurring in either the first six months of the study (months 0-6; &lt;=194 days) or the second six months of the study (months 6-12; =&gt;194 days until end of study) was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event Categorized by Participant Age</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with any adverse event by age group (12-14 and 15-17 years) is recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event Categorized by Participant Race</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with any adverse event was categorized by race. The category &quot;Other&quot; captures : American Indian or Alaskan Native; Asian, Native Hawaiian, or Other Pacific Islander; African American/African Heritage and Asian; African American/African Heritage and White; and American Indian or Alaskan Native and White.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event Categorized by Participant Gender</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with adverse events by gender is recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event That Occurred Within 3 or 5 Days of the First Dose of the Combination Tablet</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with adverse events that occurred within 3 or 5 days of their first dose of the Combination Tablet was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Tablets Taken, After Which at Least One Adverse Event Occurred Within 3 or 5 Days of Dosing With That Combination Tablet</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of events that occurred within 3 or 5 days of dosing with the combination tablet on a per tablet basis. A total of 8413, 5876, and 9989 tablets were taken by the 6 Month Completer, 12 Month Completer, and the Safety Populations, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine, Potassium, and Blood Urea Nitrogen (BUN) Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>A shift from &quot;normal to low,&quot; for example, indicates that a value was normal at baseline but low at the end of study visit. The value ranges were determined by the central laboratory. Reference ranges: ALT, 12 years old (y): 0-45 Units/liter (U/L), &gt;13 y: 0-48 U/L; AST, 12 y: 0-42 U/L, &gt;13 y 0-42 U/L; creatinine, 12 y: 27-88 micromoles/liter (UMOL/L), &gt;13 y: 44-124 UMOL/L; potassium, 12 y: 3.5-5.5 millimoles/liter (MMOL/L), &gt;13 y: 3.5-5.3 MMOL/L; BUN, 12-17 y: 24-101 milligrams (mg)/deciliter (dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematocrit and Hemoglobin Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>A shift from &quot;normal to low,&quot; for example, indicates that a value was normal at baseline but low at the end of study visit. The value ranges were determined by the central laboratory. Reference ranges: hemoglobin, 12-17 years old (y): 120-160 grams (g)/L; hematocrit (expressed as the percentage of blood occupied by red blood cells), 12-17 y: 0.360-0.490.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Height for All Study Participants at the Indicated Time Points</measure>
    <time_frame>Screening and Months 3, 6, 9, and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weight for All Study Participants at the Indicated Time Points</measure>
    <time_frame>Screening and Months 3, 6, 9, and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Body Mass Index (BMI) for All Study Participants at the Indicated Time Points</measure>
    <time_frame>Screening and Months 3, 6, 9, and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>BMI = (Weight in kilograms)/(height in centimeters/100)^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Pressure for All Study Participants at the Indicated Time Points</measure>
    <time_frame>Screening and Months 3, 6, 9, and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>At each visit, a participant's blood pressure was taken three times. The average of the three readings was then calculated for each participant at each visit (mean blood pressure). The outcome measure represents the average of the mean blood pressure of all of the study participants. SBP, systolic blood pressure; DBP, diastolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Heart Rate for All Study Participants at the Indicated Time Points</measure>
    <time_frame>Screening and Months 3, 6, 9, and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>A sitting heart rate was measured once for each participant at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram Findings at Screening and at the Final Visit as Assessed by the Investigator</measure>
    <time_frame>Screening and Final Visit (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with an electrocardiogram (ECG) status of normal, abnormal, clinically significant (CS), or not clinically significant (NCS), as determined by the Investigator, was reported. Specific definitions of ECG categorizations were not provided; investigators were expected to apply reasonable standards of clinical judgment. Normal, all ECG parameters within accepted normal ranges; abnormal, ECG finding(s) outside of normal ranges; CS, ECG with a CS abnormality that meets exclusion criteria; NCS, ECG with an abnormality not CS or meeting exclusion criteria per investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Migraine Attacks</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, or prohibited medications, was summarized. Rescue medication was additional medication taken within 24 hours of Combination Tablet. Prohibited medications: ergot, opioid, barbiturate, 5-HT1 agonist, long-acting non-steroidal anti-inflammatory drug (NSAID), short-acting NSAID-containing compound, analgesic, anti-emetic, monoamine oxidase inhibitors, St. John's Wort, angiotensin-converting enzyme inhibitor, Angiotensin II receptor blockers, anti-coagulant, anti-platelet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 24 Hours of Dosing With the Combination Tablet</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending &lt;= 24 hours after the participant was dosed with the Combination Tablet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 4 Hours of Dosing With a Combination Tablet</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending &lt;= 4 hours after the participant was dosed with the Combination Tablet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Attacks Classified as Migraine Pain-Free Within 4 Hours That Were Also Pain Free Within 2 Hours of Dosing With the Combination Tablet</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending &lt;= 4 hours after the participant was dosed with the Combination Tablet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of Headaches, Migraine Attacks, and Treated Migraine Attacks Per Month</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The average number of headaches (non-migraine and migraine attacks), migraine attacks, and treated migraine attacks per month was calculated for each participant, based on their time in the study. The outcome measure represents the average of the mean number of the headaches, migraine headaches, and treated migraines per month of the study participants in the 6 Month, 12 Month, and ITT Populations. A treated attack is defined as a migraine treated with the Combination Tablet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Total Migraines Headaches and Migraines Treated With the Combination Tablet</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total number of migraine headaches and the number of migraine headaches treated with the Combination Tablet during the study were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Migraine Attacks Rated With the Indicated Pain Severity</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of migraine attacks treated at the mild, moderate, or severe intensity were counted. Pain severity was assessed by participants based on a scale of 0-3: 0=no pain, 1=mild, 2= moderate, 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Migraine Attacks With Photophobia, Phonophobia, Nausea, Neck Pain, Sinus Pain, and Vomiting</measure>
    <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of treated migraine attacks with the reported migraine-associated symptoms of photophobia, phonophobia, nausea, neck pain, sinus pain, and vomiting were counted. Photophobia: sensitivity to light; phonophobia: sensitivity to sound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Migraine Specific Quality of Life (QOL) Questionnaire for Adolescents (MSQ-A) Score at Months 3, 6, 9, and 12</measure>
    <time_frame>Baseline and Months 3, 6, 9, and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The MSQ-A consists of 14 items measuring how migraines affect QOL: Role Function (RF)-Restrictive (items 1-7) and RF-Preventative (items 8-11), examining the degree to which performance of daily activities is limited or interrupted, respectively, by migraine; RF-Emotional (items 12-14, examining frustration/helplessness due to migraine). Dimensions (dim.) are scored independently. The 14 items are reverse coded onto a 1-6 scale; dim. are then created by summing specific item scores and transforming raw total score onto a 0-100 scale. For each dim., higher scores indicate better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Categorized by Response to Each of the 3 Global Satisfaction Questions From the Patient Perception Migraine Questionnaire-Revised (PPMQ-R) at the Screening Visit</measure>
    <time_frame>Screening</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PPMQ-R is a fully validated 32-item questionnaire assessing participant satisfaction with acute migraine medication and includes 3 questions that assess satisfaction with respect to efficacy, side effects, and overall satisfaction (i.e., How effective the medication is overall, side effects of the medication, overall satisfaction with the medication). Each item is rated on a 7-point scale ranging from &quot;very satisfied&quot; (1) to &quot;very dissatisfied&quot; (7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Categorized by Response to Each of the 3 Global Satisfaction Questions From the Patient Perception Migraine Questionaire-Revised (PPMQ-R) at Month 12</measure>
    <time_frame>End of Study/Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PPMQ-R is a fully validated 32-item questionnaire assessing participant satisfaction with acute migraine medication and includes 3 questions that assess satisfaction with respect to efficacy, side effects, and overall satisfaction (i.e., How effective the medication is overall, side effects of the medication, overall satisfaction with the medication). Each item is rated on a 7-point scale ranging from &quot;very satisfied&quot; (1) to &quot;very dissatisfied&quot; (7).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">656</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Active Drug</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combination Tablet of Treximet (sumatriptan/naproxen sodium)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Tablet of Treximet (sumatriptan/naproxen sodium)</intervention_name>
    <description>Combination Tablet of Treximet(sumatriptan/naproxen sodium)</description>
    <arm_group_label>Active Drug</arm_group_label>
    <other_name>Combination Product (sumatriptan succinate / naproxen sodium)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is between 12 and 17 years old at the Screening visit.

          -  If subject is female, she must have a negative urine pregnancy test at screening,
             does not plan to become pregnant during the course of the study and agrees to use an
             acceptable method of birth control (i.e., a method with a failure rate &lt;1% or
             abstinence) if she is/becomes sexually active.

          -  Subject has migraine with or without aura (2004 ICHD-II criteria).

          -  Subject has history suggestive of typical migraine attacks with duration of about 2
             or more hours (untreated, or unsuccessfully treated).

          -  Subject has at least 2, but not more than 8, migraine attacks per month in each of
             the 2 months prior to the Screening visit.

          -  Subject has at least a 6-month history of moderate to severe migraine attacks,
             sufficient to establish a definitive diagnosis of migraine.

          -  Subject is able to distinguish migraine from other headaches (e.g., tension-type
             headaches).

          -  Subject and subject's parent or legal guardian are willing and able to provide
             informed consent prior to entry into this treatment phase of the study.

          -  Subject and subject's parent or legal guardian are able to read and write English or
             Spanish.

          -  Subject is able to understand and complete the electronic device to report treatment
             information.

        Exclusion Criteria:

          -  Subject is &lt; 75 pounds (33.3kg).

          -  Subject has â‰¥15 headache days per month in total, retinal (ICHD-II 1.4), basilar
             (ICHD-II 1.26) or hemiplegic migraine (ICHD-II 1.25), or secondary headaches.

          -  Subject, in the investigator's opinion, is likely to have unrecognized cardiovascular
             or cerebrovascular disease (See Appendix 1, section 11.1).

          -  Subject has uncontrolled hypertension (See Appendix 2, section 11.2) or is taking any
             angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker.

          -  Subject has a history of congenital heart disease, cardiac arrhythmias requiring
             medication, or a history of a clinically significant electrocardiogram abnormality
             that, in the investigator's opinion, contraindicates participation in this study.

          -  Subject has evidence or history of any ischemic vascular diseases including: ischemic
             heart disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's
             Syndrome, or signs/symptoms consistent with any of the above.

          -  Subject has evidence or history of central nervous system pathology including stroke
             and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which
             lower the convulsive threshold; or has been treated with an antiepileptic drug for
             seizure control within 5 years prior to screening.

          -  Subject has a history of impaired hepatic or renal function that, in the
             investigator's opinion, contraindicates participation in this study.

          -  Subject has hypersensitivity, allergy, intolerance, or contraindication to the use of
             any triptan, NSAID or aspirin (including all sumatriptan and naproxen preparations)
             or has nasal polyps and asthma.

          -  Subject is currently taking, or has taken in the previous three months, a migraine
             prophylactic medication containing methysergide or dihydroergotamine; or is taking a
             medication that is not stabilized (i.e., change of dose within the past 2 months) for
             either chronic or intermittent migraine prophylaxis or for a co-morbid condition that
             is not stabilized.

          -  Subject has a recent history of regular use of opioids or barbiturates for treatment
             of his/her migraine headache and/or other non-migraine pain. Regular use is defined
             as an average of 4 days per month over the last 6 months.

          -  Subject has taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including
             herbal preparations containing St. John's Wort (Hypericum perforatum), anytime within
             the 2 weeks prior to screening through 2 weeks post final study treatment.

          -  Subject history of any bleeding disorder or is currently taking any anti-coagulant or
             any antiplatelet agent.

          -  Subject has evidence or history of any gastrointestinal surgery or GI ulceration or
             perforation in the past six months, gastrointestinal bleeding in the past year; or
             evidence or history of inflammatory bowel disease.

          -  Subject tests positive for illicit substances on toxicology screen, or has evidence
             of alcohol or substance abuse within the last year, or any concurrent medical or
             psychiatric condition which, in the investigator's judgment, will likely interfere
             with the study conduct, subject cooperation, or evaluation and interpretation of the
             study results, or which otherwise contraindicates participation in this clinical
             trial.

          -  Subject has participated in an investigational drug trial within the previous 4 weeks
             or plans to participate in another study at any time during this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chico</city>
        <state>California</state>
        <zip>95926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <zip>95628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>92585</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>East Hartford</city>
        <state>Connecticut</state>
        <zip>06118-3239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Loxahatchee</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Kentucky</state>
        <zip>42071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paw Paw</city>
        <state>Michigan</state>
        <zip>49079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Protage</city>
        <state>Michigan</state>
        <zip>49024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richland</city>
        <state>Michigan</state>
        <zip>49083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>7450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <zip>10550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504-8456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>79075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bremerton</city>
        <state>Washington</state>
        <zip>98310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McDonald SA, Hershey AD, Pearlman EM, Winner PK, Rothner DA, Linder SL, Richard NE, Derosier FJ. Long-term safety and tolerability of a single, fixed-dose tablet of sumatriptan and naproxen sodium (SumaRT/Nap) in adolescent migraineurs. Headache. 2010; 48.</citation>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <lastchanged_date>May 31, 2012</lastchanged_date>
  <firstreceived_date>June 18, 2007</firstreceived_date>
  <firstreceived_results_date>August 6, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Long-term Safety</keyword>
  <keyword>Migraine</keyword>
  <keyword>Adolescent Migraine Headache</keyword>
  <keyword>sumatriptan succinate</keyword>
  <keyword>naproxen sodium</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>85 mg Sumatriptan/500 mg Naproxen Sodium</title>
          <description>Combination Tablet: 85 milligrams (mg) sumatriptan and 500 mg naproxen sodium. A single Combination Tablet was supplied for each migraine attack, not to exceed one tablet in 24 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="656"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="363"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet criteria for treatment</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Postive drug screen</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn per medical monitor decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant had too few migraines</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Increase in number of migraines</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Increased use of concomitant medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>85 mg Sumatriptan/500 mg Naproxen Sodium</title>
          <description>Combination Tablet: 85 milligrams (mg) sumatriptan and 500 mg naproxen sodium.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="622"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Baseline data were collected in the Safety Population, comprised of all participants in the Enrolled Population (all participants entered into the trial and categorized as &quot;started&quot; in the Participant Flow module) who took at least one dose of study drug.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14.7" spread="1.68"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="367"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="255"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="527"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Africian American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="71"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>American Indian or Alaskan Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>African American/African Heritage and Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>African American/African Heritage and White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>American Indian or Alaskan Native and White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Drug-related Adverse Events</title>
        <description>The number of participants with a drug-related adverse event (AE). Frequency threshold for reporting a drug-related AE: &gt;=2% participants recorded as having at least one occurrence of a reported drug-related AE.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>Safety Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="333"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Drug-related Adverse Events</title>
            <description>The number of participants with a drug-related adverse event (AE). Frequency threshold for reporting a drug-related AE: &gt;=2% participants recorded as having at least one occurrence of a reported drug-related AE.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>At least one drug-related adverse event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                  <measurement group_id="O2" value="46"/>
                  <measurement group_id="O3" value="170"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dizziness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Muscle tightness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chest discomfort</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Paresthesia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Throat tightness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Somnolence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neck pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flushing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Event Categorized by Severity</title>
        <description>The number of participants with at least one mild (an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities), moderate (an event that is sufficiently discomforting to interfere with normal everyday activities), or severe adverse event (an event that prevents normal everyday activities) was recorded.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>Safety Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="333"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Any Adverse Event Categorized by Severity</title>
            <description>The number of participants with at least one mild (an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities), moderate (an event that is sufficiently discomforting to interfere with normal everyday activities), or severe adverse event (an event that prevents normal everyday activities) was recorded.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                  <measurement group_id="O2" value="43"/>
                  <measurement group_id="O3" value="127"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="140"/>
                  <measurement group_id="O2" value="72"/>
                  <measurement group_id="O3" value="220"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Event Categorized Over Time</title>
        <description>The number of participants with an adverse event occurring in either the first six months of the study (months 0-6; &lt;=194 days) or the second six months of the study (months 6-12; =&gt;194 days until end of study) was recorded.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>Safety Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="333"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Any Adverse Event Categorized Over Time</title>
            <description>The number of participants with an adverse event occurring in either the first six months of the study (months 0-6; &lt;=194 days) or the second six months of the study (months 6-12; =&gt;194 days until end of study) was recorded.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First six months of study</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="208"/>
                  <measurement group_id="O2" value="112"/>
                  <measurement group_id="O3" value="348"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second six months of study</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="85"/>
                  <measurement group_id="O3" value="191"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Event Categorized by Participant Age</title>
        <description>The number of participants with any adverse event by age group (12-14 and 15-17 years) is recorded.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>Safety Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="333"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Any Adverse Event Categorized by Participant Age</title>
            <description>The number of participants with any adverse event by age group (12-14 and 15-17 years) is recorded.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Ages 12-14</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="175"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ages 15-17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                  <measurement group_id="O2" value="73"/>
                  <measurement group_id="O3" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Event Categorized by Participant Race</title>
        <description>The number of participants with any adverse event was categorized by race. The category &quot;Other&quot; captures : American Indian or Alaskan Native; Asian, Native Hawaiian, or Other Pacific Islander; African American/African Heritage and Asian; African American/African Heritage and White; and American Indian or Alaskan Native and White.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all participants in the Enrolled Population who took at least one dose of the combination tablet</population>
        <group_list>
          <group group_id="O1">
            <title>85 mg Sumatriptan/500 mg Naproxen Sodium</title>
            <description>Combination Tablet: 85 milligrams (mg) sumatriptan and 500 mg naproxen sodium.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Any Adverse Event Categorized by Participant Race</title>
            <description>The number of participants with any adverse event was categorized by race. The category &quot;Other&quot; captures : American Indian or Alaskan Native; Asian, Native Hawaiian, or Other Pacific Islander; African American/African Heritage and Asian; African American/African Heritage and White; and American Indian or Alaskan Native and White.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Caucasian</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>African American</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Event Categorized by Participant Gender</title>
        <description>The number of participants with adverse events by gender is recorded.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all participants in the Enrolled Population who took at least one dose of the combination tablet</population>
        <group_list>
          <group group_id="O1">
            <title>85 mg Sumatriptan/500 mg Naproxen Sodium</title>
            <description>Combination Tablet: 85 milligrams (mg) sumatriptan and 500 mg naproxen sodium</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Any Adverse Event Categorized by Participant Gender</title>
            <description>The number of participants with adverse events by gender is recorded.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Female</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="238"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Male</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Event That Occurred Within 3 or 5 Days of the First Dose of the Combination Tablet</title>
        <description>The number of participants with adverse events that occurred within 3 or 5 days of their first dose of the Combination Tablet was recorded.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>Safety Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="333"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Any Adverse Event That Occurred Within 3 or 5 Days of the First Dose of the Combination Tablet</title>
            <description>The number of participants with adverse events that occurred within 3 or 5 days of their first dose of the Combination Tablet was recorded.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Within 3 days</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="128"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Within 5 days</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="130"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Tablets Taken, After Which at Least One Adverse Event Occurred Within 3 or 5 Days of Dosing With That Combination Tablet</title>
        <description>The number of events that occurred within 3 or 5 days of dosing with the combination tablet on a per tablet basis. A total of 8413, 5876, and 9989 tablets were taken by the 6 Month Completer, 12 Month Completer, and the Safety Populations, respectively.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet , completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>Safety Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="333"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Tablets Taken, After Which at Least One Adverse Event Occurred Within 3 or 5 Days of Dosing With That Combination Tablet</title>
            <description>The number of events that occurred within 3 or 5 days of dosing with the combination tablet on a per tablet basis. A total of 8413, 5876, and 9989 tablets were taken by the 6 Month Completer, 12 Month Completer, and the Safety Populations, respectively.</description>
            <units>tablets</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Number of tablets with an AE within 3 days</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="917"/>
                  <measurement group_id="O2" value="667"/>
                  <measurement group_id="O3" value="1116"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number of tablets with an AE within 5 days</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="970"/>
                  <measurement group_id="O2" value="706"/>
                  <measurement group_id="O3" value="1178"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine, Potassium, and Blood Urea Nitrogen (BUN) Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit</title>
        <description>A shift from â€œnormal to low,â€ for example, indicates that a value was normal at baseline but low at the end of study visit. The value ranges were determined by the central laboratory. Reference ranges: ALT, 12 years old (y): 0-45 Units/liter (U/L), &gt;13 y: 0-48 U/L; AST, 12 y: 0-42 U/L, &gt;13 y 0-42 U/L; creatinine, 12 y: 27-88 micromoles/liter (UMOL/L), &gt;13 y: 44-124 UMOL/L; potassium, 12 y: 3.5-5.5 millimoles/liter (MMOL/L), &gt;13 y: 3.5-5.3 MMOL/L; BUN, 12-17 y: 24-101 milligrams (mg)/deciliter (dL).</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet. The number of participants with an assessment may vary, depending on the number of assessments completed at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>Safety Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="330"/>
                  <measurement group_id="O2" value="179"/>
                  <measurement group_id="O3" value="565"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine, Potassium, and Blood Urea Nitrogen (BUN) Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit</title>
            <description>A shift from â€œnormal to low,â€ for example, indicates that a value was normal at baseline but low at the end of study visit. The value ranges were determined by the central laboratory. Reference ranges: ALT, 12 years old (y): 0-45 Units/liter (U/L), &gt;13 y: 0-48 U/L; AST, 12 y: 0-42 U/L, &gt;13 y 0-42 U/L; creatinine, 12 y: 27-88 micromoles/liter (UMOL/L), &gt;13 y: 44-124 UMOL/L; potassium, 12 y: 3.5-5.5 millimoles/liter (MMOL/L), &gt;13 y: 3.5-5.3 MMOL/L; BUN, 12-17 y: 24-101 milligrams (mg)/deciliter (dL).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALT, normal to high, n=330, 179, 565</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, normal to low, n=330, 179, 565</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST, normal to high, n=329, 179, 562</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST, normal to low, n=329, 179, 562</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine, normal to high, n=330, 179, 565</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine, normal to low, n=330, 179, 565</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium, normal to high, n=329, 179, 562</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium, normal to low, n=329, 179, 562</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN, normal to high, n=330, 179, 565</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN, normal to low, n=330, 179, 565</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematocrit and Hemoglobin Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit</title>
        <description>A shift from â€œnormal to low,â€ for example, indicates that a value was normal at baseline but low at the end of study visit. The value ranges were determined by the central laboratory. Reference ranges: hemoglobin, 12-17 years old (y): 120-160 grams (g)/L; hematocrit (expressed as the percentage of blood occupied by red blood cells), 12-17 y: 0.360-0.490.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet. The number of participants with an assessment may vary, depending on the number of assessments completed at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>Safety Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="318"/>
                  <measurement group_id="O2" value="176"/>
                  <measurement group_id="O3" value="546"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Hematocrit and Hemoglobin Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit</title>
            <description>A shift from â€œnormal to low,â€ for example, indicates that a value was normal at baseline but low at the end of study visit. The value ranges were determined by the central laboratory. Reference ranges: hemoglobin, 12-17 years old (y): 120-160 grams (g)/L; hematocrit (expressed as the percentage of blood occupied by red blood cells), 12-17 y: 0.360-0.490.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Hemoglobin, normal to high, n=318,176, 546</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin, normal to low, n=318,176, 546</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit, normal to high, n=318,176, 546</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit, normal to low, n=318,176, 546</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Height for All Study Participants at the Indicated Time Points</title>
        <time_frame>Screening and Months 3, 6, 9, and 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all participants in the Enrolled Population who took at least one dose of the combination tablet. The number of participants with an assessment may vary by visit, depending on the number of assessments completed at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>12-14 Years</title>
            <description>Participants who were 12-14 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O2">
            <title>15-17 Years</title>
            <description>Participants who were 15-17 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O3">
            <title>12-17 Years</title>
            <description>All participants in the Enrolled Population who took at least one dose of study drug</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="285"/>
                  <measurement group_id="O2" value="337"/>
                  <measurement group_id="O3" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Height for All Study Participants at the Indicated Time Points</title>
            <units>centimeters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Screening, n=285, 337, 622</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="160.2" spread="9.15"/>
                  <measurement group_id="O2" value="167.0" spread="8.80"/>
                  <measurement group_id="O3" value="163.9" spread="9.57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3, n=271, 308, 579</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="161.3" spread="9.09"/>
                  <measurement group_id="O2" value="167.3" spread="8.92"/>
                  <measurement group_id="O3" value="164.5" spread="9.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6, n=224, 249, 473</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="162.6" spread="9.12"/>
                  <measurement group_id="O2" value="167.3" spread="8.81"/>
                  <measurement group_id="O3" value="165.1" spread="9.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 9, n=198, 221, 419</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="163.8" spread="8.92"/>
                  <measurement group_id="O2" value="167.6" spread="8.39"/>
                  <measurement group_id="O3" value="165.8" spread="8.84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 12, n=178, 198, 376</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="165.3" spread="8.86"/>
                  <measurement group_id="O2" value="167.9" spread="8.70"/>
                  <measurement group_id="O3" value="166.7" spread="8.86"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weight for All Study Participants at the Indicated Time Points</title>
        <time_frame>Screening and Months 3, 6, 9, and 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all participants in the Enrolled Population who took at least one dose of the combination tablet. The number of participants with an assessment may vary, depending on the number of assessments completed at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>12-14 Years</title>
            <description>Participants who were 12-14 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O2">
            <title>15-17 Years</title>
            <description>Participants who were 15-17 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O3">
            <title>12-17 Years</title>
            <description>All participants in the Enrolled Population who took at least one dose of study drug</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="285"/>
                  <measurement group_id="O2" value="337"/>
                  <measurement group_id="O3" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Weight for All Study Participants at the Indicated Time Points</title>
            <units>kilograms</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Screening, n=285, 337, 622</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57.02" spread="15.450"/>
                  <measurement group_id="O2" value="66.57" spread="16.824"/>
                  <measurement group_id="O3" value="62.19" spread="16.881"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3, n=270, 306, 576</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58.01" spread="16.012"/>
                  <measurement group_id="O2" value="66.61" spread="16.921"/>
                  <measurement group_id="O3" value="62.58" spread="17.037"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6, n=223, 248, 471</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60.20" spread="16.976"/>
                  <measurement group_id="O2" value="66.61" spread="16.864"/>
                  <measurement group_id="O3" value="63.57" spread="17.200"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 9, n=197, 220, 417</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61.24" spread="17.149"/>
                  <measurement group_id="O2" value="66.90" spread="17.169"/>
                  <measurement group_id="O3" value="64.23" spread="17.372"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 12, n=178, 198, 376</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62.92" spread="17.406"/>
                  <measurement group_id="O2" value="67.35" spread="17.952"/>
                  <measurement group_id="O3" value="65.25" spread="17.810"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Body Mass Index (BMI) for All Study Participants at the Indicated Time Points</title>
        <description>BMI = (Weight in kilograms)/(height in centimeters/100)^2</description>
        <time_frame>Screening and Months 3, 6, 9, and 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all participants in the Enrolled Population who took at least one dose of the combination tablet. The number of participants with an assessment may vary, depending on the number of assessments completed at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>12-14 Years</title>
            <description>Participants who were 12-14 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O2">
            <title>15-17 Years</title>
            <description>Participants who were 15-17 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O3">
            <title>12-17 Years</title>
            <description>All participants in the Enrolled Population who took at least one dose of study drug</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="285"/>
                  <measurement group_id="O2" value="337"/>
                  <measurement group_id="O3" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Body Mass Index (BMI) for All Study Participants at the Indicated Time Points</title>
            <description>BMI = (Weight in kilograms)/(height in centimeters/100)^2</description>
            <units>kilograms per meters squared</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Screening, n=285, 337, 622</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.01" spread="4.611"/>
                  <measurement group_id="O2" value="23.77" spread="5.249"/>
                  <measurement group_id="O3" value="22.97" spread="5.040"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3, n=270, 306, 576</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.09" spread="4.740"/>
                  <measurement group_id="O2" value="23.71" spread="5.267"/>
                  <measurement group_id="O3" value="22.95" spread="5.087"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6, n=223, 248, 471</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.54" spread="4.949"/>
                  <measurement group_id="O2" value="23.74" spread="5.455"/>
                  <measurement group_id="O3" value="23.17" spread="5.251"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 9, n= 197, 220, 417</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.58" spread="4.904"/>
                  <measurement group_id="O2" value="23.74" spread="5.431"/>
                  <measurement group_id="O3" value="23.20" spread="5.215"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 12, n=178, 198, 376</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.81" spread="4.969"/>
                  <measurement group_id="O2" value="23.79" spread="5.633"/>
                  <measurement group_id="O3" value="23.33" spread="5.345"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Pressure for All Study Participants at the Indicated Time Points</title>
        <description>At each visit, a participantâ€™s blood pressure was taken three times. The average of the three readings was then calculated for each participant at each visit (mean blood pressure). The outcome measure represents the average of the mean blood pressure of all of the study participants. SBP, systolic blood pressure; DBP, diastolic blood pressure.</description>
        <time_frame>Screening and Months 3, 6, 9, and 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all participants in the Enrolled Population who took at least one dose of the combination tablet. The number of participants with an assessment may vary, depending on the number of assessments completed at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>12-14 Years</title>
            <description>Participants who were 12-14 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O2">
            <title>15-17 Years</title>
            <description>Participants who were 15-17 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O3">
            <title>12-17 Years</title>
            <description>All participants in the Enrolled Population who took at least one dose of study drug</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="285"/>
                  <measurement group_id="O2" value="337"/>
                  <measurement group_id="O3" value="622"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Blood Pressure for All Study Participants at the Indicated Time Points</title>
            <description>At each visit, a participantâ€™s blood pressure was taken three times. The average of the three readings was then calculated for each participant at each visit (mean blood pressure). The outcome measure represents the average of the mean blood pressure of all of the study participants. SBP, systolic blood pressure; DBP, diastolic blood pressure.</description>
            <units>millimeters of mercury (mmHg)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>SBP, Screening, n=285, 337, 622</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107.4" spread="10.08"/>
                  <measurement group_id="O2" value="110.2" spread="10.15"/>
                  <measurement group_id="O3" value="108.9" spread="10.21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SBP, Month 3, n=270, 308, 578</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107.2" spread="10.67"/>
                  <measurement group_id="O2" value="111.1" spread="10.19"/>
                  <measurement group_id="O3" value="109.3" spread="10.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SBP, Month 6, n=224, 249, 473</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="109.2" spread="10.37"/>
                  <measurement group_id="O2" value="112.0" spread="10.39"/>
                  <measurement group_id="O3" value="110.6" spread="10.46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SBP, Month 9, n=198, 221, 419</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="109.6" spread="10.55"/>
                  <measurement group_id="O2" value="112.7" spread="10.63"/>
                  <measurement group_id="O3" value="111.2" spread="10.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SBP, Month 12, n=178, 198, 376</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="111.0" spread="10.78"/>
                  <measurement group_id="O2" value="112.1" spread="10.22"/>
                  <measurement group_id="O3" value="111.5" spread="10.49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DBP, Screening, n=285, 337, 622</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66.2" spread="7.72"/>
                  <measurement group_id="O2" value="69.0" spread="7.24"/>
                  <measurement group_id="O3" value="67.7" spread="7.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DBP, Month 3, n=270, 308, 578</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65.7" spread="7.33"/>
                  <measurement group_id="O2" value="68.4" spread="7.84"/>
                  <measurement group_id="O3" value="67.1" spread="7.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DBP, Month 3, n=270, 308, 578</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66.1" spread="7.29"/>
                  <measurement group_id="O2" value="68.4" spread="7.68"/>
                  <measurement group_id="O3" value="67.3" spread="7.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DBP, Month 9, n=198, 221, 419</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65.6" spread="6.79"/>
                  <measurement group_id="O2" value="68.9" spread="7.30"/>
                  <measurement group_id="O3" value="67.3" spread="7.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DBP, Month 12, n=178, 198, 376</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66.6" spread="8.40"/>
                  <measurement group_id="O2" value="69.9" spread="7.35"/>
                  <measurement group_id="O3" value="68.3" spread="8.03"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Heart Rate for All Study Participants at the Indicated Time Points</title>
        <description>A sitting heart rate was measured once for each participant at each visit.</description>
        <time_frame>Screening and Months 3, 6, 9, and 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all participants in the Enrolled Population who took at least one dose of the combination tablet. The number of participants with an assessment may vary, depending on the number of assessments completed at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>12-14 Years</title>
            <description>Participants who were 12-14 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O2">
            <title>15-17 Years</title>
            <description>Participants who were 15-17 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O3">
            <title>12-17 Years</title>
            <description>All participants in the Enrolled Population who took at least one dose of study drug</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="284"/>
                  <measurement group_id="O2" value="336"/>
                  <measurement group_id="O3" value="620"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Heart Rate for All Study Participants at the Indicated Time Points</title>
            <description>A sitting heart rate was measured once for each participant at each visit.</description>
            <units>beats per minute</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Screening, n=284, 336, 620</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75.8" spread="11.58"/>
                  <measurement group_id="O2" value="73.0" spread="10.20"/>
                  <measurement group_id="O3" value="7.43" spread="10.93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3, n=266, 305, 571</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.9" spread="11.57"/>
                  <measurement group_id="O2" value="75.6" spread="11.57"/>
                  <measurement group_id="O3" value="76.2" spread="11.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6, n=221, 247, 468</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77.5" spread="10.87"/>
                  <measurement group_id="O2" value="75.4" spread="10.22"/>
                  <measurement group_id="O3" value="76.4" spread="10.57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 9, n=198, 221, 419</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.9" spread="11.43"/>
                  <measurement group_id="O2" value="75.4" spread="11.13"/>
                  <measurement group_id="O3" value="76.1" spread="11.28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 12, n=178, 198, 376</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.8" spread="12.17"/>
                  <measurement group_id="O2" value="74.7" spread="10.41"/>
                  <measurement group_id="O3" value="75.7" spread="11.31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Electrocardiogram Findings at Screening and at the Final Visit as Assessed by the Investigator</title>
        <description>The number of participants with an electrocardiogram (ECG) status of normal, abnormal, clinically significant (CS), or not clinically significant (NCS), as determined by the Investigator, was reported. Specific definitions of ECG categorizations were not provided; investigators were expected to apply reasonable standards of clinical judgment. Normal, all ECG parameters within accepted normal ranges; abnormal, ECG finding(s) outside of normal ranges; CS, ECG with a CS abnormality that meets exclusion criteria; NCS, ECG with an abnormality not CS or meeting exclusion criteria per investigator.</description>
        <time_frame>Screening and Final Visit (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all participants in the Enrolled Population who took at least one dose of the combination tablet. The number of participants with an assessment may vary, depending on the number of assessments completed at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>12-14 Years</title>
            <description>Participants who were 12-14 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O2">
            <title>15-17 Years</title>
            <description>Participants who were 15-17 years old at the time of the Screening Visit</description>
          </group>
          <group group_id="O3">
            <title>12-17 Years</title>
            <description>All participants in the Enrolled Population who took at least one dose of study drug</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="284"/>
                  <measurement group_id="O2" value="337"/>
                  <measurement group_id="O3" value="621"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Abnormal Electrocardiogram Findings at Screening and at the Final Visit as Assessed by the Investigator</title>
            <description>The number of participants with an electrocardiogram (ECG) status of normal, abnormal, clinically significant (CS), or not clinically significant (NCS), as determined by the Investigator, was reported. Specific definitions of ECG categorizations were not provided; investigators were expected to apply reasonable standards of clinical judgment. Normal, all ECG parameters within accepted normal ranges; abnormal, ECG finding(s) outside of normal ranges; CS, ECG with a CS abnormality that meets exclusion criteria; NCS, ECG with an abnormality not CS or meeting exclusion criteria per investigator.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Screening, normal, n=284, 337, 621</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="270"/>
                  <measurement group_id="O3" value="494"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Screening, abnormal, NCS, n=284, 337, 621</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="67"/>
                  <measurement group_id="O3" value="127"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Screening, abnormal, CS, n=284, 337, 621</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit, Normal, n=248, 294, 542</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="196"/>
                  <measurement group_id="O2" value="220"/>
                  <measurement group_id="O3" value="416"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit, abnormal, NCS, n=248, 294, 542</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="74"/>
                  <measurement group_id="O3" value="126"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit, abnormal, CS, n=248, 294, 542</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treated Migraine Attacks</title>
        <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, or prohibited medications, was summarized. Rescue medication was additional medication taken within 24 hours of Combination Tablet. Prohibited medications: ergot, opioid, barbiturate, 5-HT1 agonist, long-acting non-steroidal anti-inflammatory drug (NSAID), short-acting NSAID-containing compound, analgesic, anti-emetic, monoamine oxidase inhibitors, St. Johnâ€™s Wort, angiotensin-converting enzyme inhibitor, Angiotensin II receptor blockers, anti-coagulant, anti-platelet.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) Population: all participants who took at least one dose of study drug and had at least one post-treatment migraine assessment</population>
        <group_list>
          <group group_id="O1">
            <title>85 mg Sumatriptan/500 mg Naproxen Sodium</title>
            <description>Combination Tablet: 85 milligrams (mg) sumatriptan and 500 mg naproxen sodium</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="591"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Treated Migraine Attacks</title>
            <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, or prohibited medications, was summarized. Rescue medication was additional medication taken within 24 hours of Combination Tablet. Prohibited medications: ergot, opioid, barbiturate, 5-HT1 agonist, long-acting non-steroidal anti-inflammatory drug (NSAID), short-acting NSAID-containing compound, analgesic, anti-emetic, monoamine oxidase inhibitors, St. Johnâ€™s Wort, angiotensin-converting enzyme inhibitor, Angiotensin II receptor blockers, anti-coagulant, anti-platelet.</description>
            <units>treated migraine attacks</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>All Migraines</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8517"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Migraines Without Rescue Medication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7791"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Migraines Without Rescue or Prohibited Medication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7657"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 24 Hours of Dosing With the Combination Tablet</title>
        <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending &lt;= 24 hours after the participant was dosed with the Combination Tablet.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population: all participants who took at least one dose of study drug and had at least one post-treatment migraine assessment</population>
        <group_list>
          <group group_id="O1">
            <title>85 mg Sumatriptan/500 mg Naproxen Sodium</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="591"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 24 Hours of Dosing With the Combination Tablet</title>
            <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending &lt;= 24 hours after the participant was dosed with the Combination Tablet.</description>
            <units>treated migraine attacks</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>All Migraines</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6400"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Migraines Without Rescue Medication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6142"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Migraines Without Rescue or Prohibited Medication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6052"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 4 Hours of Dosing With a Combination Tablet</title>
        <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending &lt;= 4 hours after the participant was dosed with the Combination Tablet.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population: all participants who took at least one dose of study drug and had at least one post-treatment migraine assessment</population>
        <group_list>
          <group group_id="O1">
            <title>85 mg Sumatriptan/500 mg Naproxen Sodium</title>
            <description>Combination Tablet: 85 milligrams (mg) sumatriptan and 500 mg naproxen sodium</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="591"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 4 Hours of Dosing With a Combination Tablet</title>
            <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending &lt;= 4 hours after the participant was dosed with the Combination Tablet.</description>
            <units>treated migraine attacks</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>All Migraines</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5076"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Migraines Without Rescue Medication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5020"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Migraines Without Rescue or Prohibited Medication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5017"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treated Attacks Classified as Migraine Pain-Free Within 4 Hours That Were Also Pain Free Within 2 Hours of Dosing With the Combination Tablet</title>
        <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending &lt;= 4 hours after the participant was dosed with the Combination Tablet.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population: all participants who took at least one dose of study drug and had at least one post-treatment migraine assessment</population>
        <group_list>
          <group group_id="O1">
            <title>85 mg Sumatriptan/500 mg Naproxen Sodium</title>
            <description>Combination Tablet: 85 milligrams (mg) sumatriptan and 500 mg naproxen sodium</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="591"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Treated Attacks Classified as Migraine Pain-Free Within 4 Hours That Were Also Pain Free Within 2 Hours of Dosing With the Combination Tablet</title>
            <description>The number of migraine attacks eligible for evaluation, not associated with rescue medication use, and not associated with either rescue medication use or prohibited medications were counted. Migraine Pain Free was defined as the migraine attack ending &lt;= 4 hours after the participant was dosed with the Combination Tablet.</description>
            <units>treated migraine attacks</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>All Migraines</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3623"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Migraines Without Rescue Medication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3598"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Migraines Without Rescue or Prohibited Medication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3596"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of Headaches, Migraine Attacks, and Treated Migraine Attacks Per Month</title>
        <description>The average number of headaches (non-migraine and migraine attacks), migraine attacks, and treated migraine attacks per month was calculated for each participant, based on their time in the study. The outcome measure represents the average of the mean number of the headaches, migraine headaches, and treated migraines per month of the study participants in the 6 Month, 12 Month, and ITT Populations. A treated attack is defined as a migraine treated with the Combination Tablet.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>ITT Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet and had at least one post-treatment migraine assessment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="333"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="591"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Average Number of Headaches, Migraine Attacks, and Treated Migraine Attacks Per Month</title>
            <description>The average number of headaches (non-migraine and migraine attacks), migraine attacks, and treated migraine attacks per month was calculated for each participant, based on their time in the study. The outcome measure represents the average of the mean number of the headaches, migraine headaches, and treated migraines per month of the study participants in the 6 Month, 12 Month, and ITT Populations. A treated attack is defined as a migraine treated with the Combination Tablet.</description>
            <units>events</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Headaches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.3" spread="2.19"/>
                  <measurement group_id="O2" value="3.9" spread="2.29"/>
                  <measurement group_id="O3" value="3.0" spread="2.49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Migraines</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.2" spread="1.17"/>
                  <measurement group_id="O2" value="2.6" spread="1.09"/>
                  <measurement group_id="O3" value="1.8" spread="1.23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treated migraine attacks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.9" spread="1.05"/>
                  <measurement group_id="O2" value="2.4" spread="0.97"/>
                  <measurement group_id="O3" value="1.5" spread="1.11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Total Migraines Headaches and Migraines Treated With the Combination Tablet</title>
        <description>The total number of migraine headaches and the number of migraine headaches treated with the Combination Tablet during the study were summarized.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>ITT Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet and had at least one post-treatment migraine assessment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="333"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="591"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Total Migraines Headaches and Migraines Treated With the Combination Tablet</title>
            <description>The total number of migraine headaches and the number of migraine headaches treated with the Combination Tablet during the study were summarized.</description>
            <units>migraine attacks</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Total Migraines</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8290"/>
                  <measurement group_id="O2" value="5851"/>
                  <measurement group_id="O3" value="9937"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treated Migraines</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7318"/>
                  <measurement group_id="O2" value="5234"/>
                  <measurement group_id="O3" value="8517"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Migraine Attacks Rated With the Indicated Pain Severity</title>
        <description>The number of migraine attacks treated at the mild, moderate, or severe intensity were counted. Pain severity was assessed by participants based on a scale of 0-3: 0=no pain, 1=mild, 2= moderate, 3=severe.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>ITT Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet and had at least one post-treatment migraine assessment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="333"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="591"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Migraine Attacks Rated With the Indicated Pain Severity</title>
            <description>The number of migraine attacks treated at the mild, moderate, or severe intensity were counted. Pain severity was assessed by participants based on a scale of 0-3: 0=no pain, 1=mild, 2= moderate, 3=severe.</description>
            <units>treated migraine attacks</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>No pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1373"/>
                  <measurement group_id="O2" value="1009"/>
                  <measurement group_id="O3" value="1619"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3555"/>
                  <measurement group_id="O2" value="2535"/>
                  <measurement group_id="O3" value="4132"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2385"/>
                  <measurement group_id="O2" value="1686"/>
                  <measurement group_id="O3" value="2759"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treated Migraine Attacks With Photophobia, Phonophobia, Nausea, Neck Pain, Sinus Pain, and Vomiting</title>
        <description>The number of treated migraine attacks with the reported migraine-associated symptoms of photophobia, phonophobia, nausea, neck pain, sinus pain, and vomiting were counted. Photophobia: sensitivity to light; phonophobia: sensitivity to sound.</description>
        <time_frame>Baseline through End of Study (up to Month 12)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet</population>
        <group_list>
          <group group_id="O1">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
          <group group_id="O3">
            <title>ITT Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet and had at least one post-treatment migraine assessment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="333"/>
                  <measurement group_id="O2" value="181"/>
                  <measurement group_id="O3" value="591"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Treated Migraine Attacks With Photophobia, Phonophobia, Nausea, Neck Pain, Sinus Pain, and Vomiting</title>
            <description>The number of treated migraine attacks with the reported migraine-associated symptoms of photophobia, phonophobia, nausea, neck pain, sinus pain, and vomiting were counted. Photophobia: sensitivity to light; phonophobia: sensitivity to sound.</description>
            <units>treated migraine attacks</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Photophobia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5608"/>
                  <measurement group_id="O2" value="4064"/>
                  <measurement group_id="O3" value="6528"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Phonophobia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5221"/>
                  <measurement group_id="O2" value="3725"/>
                  <measurement group_id="O3" value="6063"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3120"/>
                  <measurement group_id="O2" value="2173"/>
                  <measurement group_id="O3" value="3690"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neck pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3050"/>
                  <measurement group_id="O2" value="2172"/>
                  <measurement group_id="O3" value="3540"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sinus pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2052"/>
                  <measurement group_id="O2" value="1424"/>
                  <measurement group_id="O3" value="2428"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="555"/>
                  <measurement group_id="O2" value="375"/>
                  <measurement group_id="O3" value="682"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Migraine Specific Quality of Life (QOL) Questionnaire for Adolescents (MSQ-A) Score at Months 3, 6, 9, and 12</title>
        <description>The MSQ-A consists of 14 items measuring how migraines affect QOL: Role Function (RF)-Restrictive (items 1-7) and RF-Preventative (items 8-11), examining the degree to which performance of daily activities is limited or interrupted, respectively, by migraine; RF-Emotional (items 12-14, examining frustration/helplessness due to migraine). Dimensions (dim.) are scored independently. The 14 items are reverse coded onto a 1-6 scale; dim. are then created by summing specific item scores and transforming raw total score onto a 0-100 scale. For each dim., higher scores indicate better health status.</description>
        <time_frame>Baseline and Months 3, 6, 9, and 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet. Due to data collection and/or assignment of a collected assessment to a visit, the number of participants analyzed at a given visit could vary.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet and had at least one post-treatment migraine assessment</description>
          </group>
          <group group_id="O2">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="457"/>
                  <measurement group_id="O2" value="160"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in the Migraine Specific Quality of Life (QOL) Questionnaire for Adolescents (MSQ-A) Score at Months 3, 6, 9, and 12</title>
            <description>The MSQ-A consists of 14 items measuring how migraines affect QOL: Role Function (RF)-Restrictive (items 1-7) and RF-Preventative (items 8-11), examining the degree to which performance of daily activities is limited or interrupted, respectively, by migraine; RF-Emotional (items 12-14, examining frustration/helplessness due to migraine). Dimensions (dim.) are scored independently. The 14 items are reverse coded onto a 1-6 scale; dim. are then created by summing specific item scores and transforming raw total score onto a 0-100 scale. For each dim., higher scores indicate better health status.</description>
            <units>points on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Role restrictive, Month 3, n=457, 160</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.1" spread="1.145"/>
                  <measurement group_id="O2" value="9.0" spread="1.952"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role restrictive, Month 6, n=366, 160</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.5" spread="1.302"/>
                  <measurement group_id="O2" value="8.2" spread="1.972"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role restrictive, Month 9, n=315, 148</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.7" spread="1.475"/>
                  <measurement group_id="O2" value="9.0" spread="2.155"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role restrictive, Month 12, n=291, 153</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.7" spread="1.530"/>
                  <measurement group_id="O2" value="11.5" spread="2.117"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role preventative, Month 3, n=457, 160</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.9" spread="1.110"/>
                  <measurement group_id="O2" value="9.6" spread="1.974"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role preventative, Month 6, n=366, 160</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.8" spread="1.212"/>
                  <measurement group_id="O2" value="8.3" spread="1.890"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role preventative, Month 9, n=315, 148</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.4" spread="1.473"/>
                  <measurement group_id="O2" value="8.2" spread="2.234"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role preventative, Month 12, n=291, 153</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.8" spread="1.441"/>
                  <measurement group_id="O2" value="8.4" spread="1.959"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role emotional , Month 3, n=457, 160</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.1" spread="1.287"/>
                  <measurement group_id="O2" value="7.9" spread="2.223"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role emotional, Month 6, n=366, 160</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.6" spread="1.441"/>
                  <measurement group_id="O2" value="7.2" spread="2.136"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role emotional, Month 9, n=315, 148</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.5" spread="1.625"/>
                  <measurement group_id="O2" value="9.0" spread="2.411"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role emotional, Month 12, n=291, 153</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.4" spread="1.694"/>
                  <measurement group_id="O2" value="7.1" spread="2.461"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Categorized by Response to Each of the 3 Global Satisfaction Questions From the Patient Perception Migraine Questionnaireâ€“Revised (PPMQ-R) at the Screening Visit</title>
        <description>The PPMQ-R is a fully validated 32-item questionnaire assessing participant satisfaction with acute migraine medication and includes 3 questions that assess satisfaction with respect to efficacy, side effects, and overall satisfaction (i.e., How effective the medication is overall, side effects of the medication, overall satisfaction with the medication). Each item is rated on a 7-point scale ranging from â€œvery satisfiedâ€ (1) to â€œvery dissatisfiedâ€ (7).</description>
        <time_frame>Screening</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet. Due to data collection and/or assignment of a collected assessment to a visit, the number of participants analyzed at a given visit could vary.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet drug and had at least one post-treatment migraine assessment</description>
          </group>
          <group group_id="O2">
            <title>6 Month Completer Population</title>
            <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O3">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="562"/>
                  <measurement group_id="O2" value="316"/>
                  <measurement group_id="O3" value="174"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Categorized by Response to Each of the 3 Global Satisfaction Questions From the Patient Perception Migraine Questionnaireâ€“Revised (PPMQ-R) at the Screening Visit</title>
            <description>The PPMQ-R is a fully validated 32-item questionnaire assessing participant satisfaction with acute migraine medication and includes 3 questions that assess satisfaction with respect to efficacy, side effects, and overall satisfaction (i.e., How effective the medication is overall, side effects of the medication, overall satisfaction with the medication). Each item is rated on a 7-point scale ranging from â€œvery satisfiedâ€ (1) to â€œvery dissatisfiedâ€ (7).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Overall Efficacy, Very Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="163"/>
                  <measurement group_id="O2" value="102"/>
                  <measurement group_id="O3" value="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Somewhat Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="192"/>
                  <measurement group_id="O2" value="113"/>
                  <measurement group_id="O3" value="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Somewhat Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Very Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Very Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                  <measurement group_id="O2" value="89"/>
                  <measurement group_id="O3" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="166"/>
                  <measurement group_id="O2" value="87"/>
                  <measurement group_id="O3" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Somewhat Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="69"/>
                  <measurement group_id="O3" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Somewhat Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Very Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Very Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="192"/>
                  <measurement group_id="O2" value="113"/>
                  <measurement group_id="O3" value="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Somewhat Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="164"/>
                  <measurement group_id="O2" value="94"/>
                  <measurement group_id="O3" value="56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment Satisfaction, Somewhat Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Very Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Categorized by Response to Each of the 3 Global Satisfaction Questions From the Patient Perception Migraine Questionaireâ€“Revised (PPMQ-R) at Month 12</title>
        <description>The PPMQ-R is a fully validated 32-item questionnaire assessing participant satisfaction with acute migraine medication and includes 3 questions that assess satisfaction with respect to efficacy, side effects, and overall satisfaction (i.e., How effective the medication is overall, side effects of the medication, overall satisfaction with the medication). Each item is rated on a 7-point scale ranging from â€œvery satisfiedâ€ (1) to â€œvery dissatisfiedâ€ (7).</description>
        <time_frame>End of Study/Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Enrolled Population: all participants entered into the trial and dispensed the Combination Tablet, regardless of whether they ever took the Combination Tablet. Due to data collection and/or assignment of a collected assessment to a visit, the number of participants analyzed at a given visit could vary.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Population</title>
            <description>Participants in the Enrolled Population who took at least one dose of the combination tablet and had at least one post-treatment migraine assessment</description>
          </group>
          <group group_id="O2">
            <title>6 Month Completer Population</title>
            <description>Participant in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
          </group>
          <group group_id="O3">
            <title>12 Month Completer Population</title>
            <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="171"/>
                  <measurement group_id="O2" value="144"/>
                  <measurement group_id="O3" value="110"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Categorized by Response to Each of the 3 Global Satisfaction Questions From the Patient Perception Migraine Questionaireâ€“Revised (PPMQ-R) at Month 12</title>
            <description>The PPMQ-R is a fully validated 32-item questionnaire assessing participant satisfaction with acute migraine medication and includes 3 questions that assess satisfaction with respect to efficacy, side effects, and overall satisfaction (i.e., How effective the medication is overall, side effects of the medication, overall satisfaction with the medication). Each item is rated on a 7-point scale ranging from â€œvery satisfiedâ€ (1) to â€œvery dissatisfiedâ€ (7).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Overall Efficacy, Very Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="59"/>
                  <measurement group_id="O3" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="63"/>
                  <measurement group_id="O3" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Somewhat Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Somewhat Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Efficacy, Very Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Very Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="49"/>
                  <measurement group_id="O3" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Somewhat Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="21"/>
                  <measurement group_id="O3" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Somewhat Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side Effects, Very Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Very Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="64"/>
                  <measurement group_id="O3" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76"/>
                  <measurement group_id="O2" value="61"/>
                  <measurement group_id="O3" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Somewhat Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment Satisfaction, Somewhat Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Treatment Satisfaction, Very Dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Safety Population</title>
          <description>Participants in the Enrolled Population who took at least one dose of the combination tablet</description>
        </group>
        <group group_id="E2">
          <title>6 Month Completer Population</title>
          <description>Participants in the Enrolled Population who were treated with at least one dose of the combination tablet, completed at least one study visit (3- or 6-month visit), provided data for at least 6 migraines, and who continued in the study for at least 166 days</description>
        </group>
        <group group_id="E3">
          <title>12 Month Completer Population</title>
          <description>Participants in the Enrolled and 6 Month Completer Populations who completed at least one study visit in the second six-month period (9- or 12-month visit), provided data for at least 12 migraines, and who continued in the study for at least 346 days. The 12 Month Completer Population is a subset of those participants who completed or remained in the study for at least 346 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolytic anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Spontaneous abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Migraine (worsening)</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
